J&J Hopes Eprex Experience Will Influence Follow-On Biologics Regulatory Pathway
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson is discussing its Eprex manufacturing complications in Europe with regulators working to develop a follow-on biologics pathway
You may also be interested in...
Analytical Test Series Would Allow Characterization Of Follow-On Biologics – GPhA
"No 'one' analytical method is currently capable of such comprehensive analysis," a Generic Pharmaceutical Association white paper states. Previously reported characterization problems were due to inappropriate or misinterpreted tests, GPhA maintains.
Analytical Test Series Would Allow Characterization Of Follow-On Biologics – GPhA
"No 'one' analytical method is currently capable of such comprehensive analysis," a Generic Pharmaceutical Association white paper states. Previously reported characterization problems were due to inappropriate or misinterpreted tests, GPhA maintains.
BIO Comments On Follow-On Biologics Will Include Manufacturing Anecdotes
FDA officials' questions to industry reps during public workshop focus on the level of studies that should be required for follow-on biologic applications, particularly in comparison to requirements for manufacturing process changes by innovators.